



INVESTOR UPDATE

BSE: 506690	NSE: UNICHEMLAB	Reuters: UNLB.BO	Bloomberg: UN@IN
-------------	-----------------	------------------	------------------

Mumbai, April 7, 2011

Unichem Laboratories receives ANDA approval from USFDA for DIVALPROEX SODIUM DELAYED RELEASE TABLETS

Unichem laboratories Limited are pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (U.S. FDA) for Divalproex Sodium Delayed Release Tablets.

Divalproex Sodium Delayed Release Tablets USP 125mg, 250mg and 500mg (Valproic Acid Activity) are therapeutically equivalent to DEPAKOTE® Delayed-Release Tablets USP 125mg, 250mg, and 500mg from Abbott Laboratories. Divalproex Sodium formulations have annual sales of approximately USD 590 million in the US.

Divalproex Sodium Delayed-Release Tablets, USP are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Divalproex Sodium Delayed-Release Tablets, USP also are indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types that include absence seizures. Divalproex Sodium Delayed-Release Tablets, USP also are indicated for the treatment of manic episodes associated with bipolar disorder and prophylaxis of migraine headaches.

The product will be commercialized from Unichem's Ghaziabad plant. **This ANDA** approval will increase the presence of Unichem in US market. Unichem already has 9 other ANDA's duly approved and there are some more ANDA's in pipeline.

About Unichem Laboratories Limited

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, and orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms.

More information about the company can be found at www.unichemlabs.com.

Contacts:

Mr. M Gundu Rao
Tel: +912266888380
Cell: +919820228944

✉: gundurao@unichemlabs.com

Mr. Rakesh Parikh
Tel: +912266888414
Cell: +919892925555

✉: rparikh@unichemlabs.com

Mr. K Subharaman
Tel: +912266888404
Cell: +919833031121

✉: subharamank@unichemlabs.com

This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

-o0o-